Half Year 2025 Thor Medical ASA Earnings Call Transcript
Key Points
- Thor Medical ASA (FRA:8NN) has a patent-pending technology for producing alpha-emitting isotopes, positioning it as a potential market leader in the radiopharmaceutical sector.
- The company has a significant order backlog of NOK700 million, indicating strong demand for its products.
- Thor Medical ASA has successfully raised capital to expand its AlphaOne plant by 40% without affecting the project timeline, demonstrating effective financial management.
- Strategic agreements have been signed with major players in the industry, including a 50% increased commitment from AdvanCell, showcasing strong commercial partnerships.
- The company has achieved its first revenue from a big pharma company, validating its technology and market acceptance.
- Thor Medical ASA reported a negative EBITDA of NOK23 million for the first half of 2025, highlighting ongoing financial losses.
- The company is still in the early stages of its commercial operations, with profitability not expected until the end of 2027.
- There is a risk associated with the scalability of the production process, although the company claims to have agreements in place to mitigate this.
- Despite positive developments in the lead-212 field, Thor Medical ASA's stock has not reacted favorably, indicating potential market disconnect or lack of investor awareness.
- The company faces competition from other firms with reactor-based methods and vertically integrated pharmaceutical companies, which could impact its market position.
Good morning. It's a true pleasure to stand here today in front of you to share Thor Medical's first half year results. My name is Jasper. And in the next 25 to 30 minutes, my dear colleague, Brede and myself, will walk you through our achievements in the first six months this year, and we also share some lights on our plans and the road forward for Thor Medical.
Now before we dive into the presentation, actually, this is a very important event for us, not only because it's important for the stock market, it is important because we have moved our office actually to this location. And for the first time, we basically stand here, next to our office and have a crowd to speak of, which is very nice. Thanks all of you for joining today here to talk to us.
Before we dive into the presentation, the usual disclaimer. This presentation contains forward-looking statements, and they have to be seen in combination with the verbal delivery.
Let's recap a bit what this company is all about. So we have this ambitious plan of being the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
